利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.03 秒)

    Quinoline Derivatives as NK-3 and NK-2 Antagonists
    3.
    发明申请
    Quinoline Derivatives as NK-3 and NK-2 Antagonists 审中-公开
    喹啉衍生物作为NK-3和NK-2拮抗剂

    公开(公告)号：US20070015766A1

    公开(公告)日：2007-01-18

    申请号：US11426414

    申请日：2006-06-26

    申请人： Carlo Farina ,  Stefania Gagliardi ,  Giuseppe Giardina ,  Mario Grugni ,  Marisa Martinelli ,  Guy Marguerite Marie Gerard Nadler

    发明人： Carlo Farina ,  Stefania Gagliardi ,  Giuseppe Giardina ,  Mario Grugni ,  Marisa Martinelli ,  Guy Marguerite Marie Gerard Nadler

    IPC分类号： A61K31/496 ,  C07D403/02

    CPC分类号： C07D401/12 ,  C07D215/52

    摘要： Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: wherein: R1 is H or alkyl; R2 is aryl, cycloalkyl or heteroaryl; R3 is H or C1-3 alkyl, optionally substituted by one or more fluorines; R4 is H, R8NR9R10, R11R13 or R11R12R13; or R5 is branched or linear alkyl, cycloalkyl, aryl, arylalkyl, or a single or fused ring aromatic heterocyclic group; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and the use of such compounds and composition in medicine.

    摘要翻译： 某些下式（I）化合物或其药学上可接受的盐或水合物：其中：R 1是H或烷基; R 2是芳基，环烷基或杂芳基; R 3是H或C 1-3烷基，任选被一个或多个氟取代; R 4是H，R 8 NR 9 R 10，R 11 R 13或13个R 12 R 13 13; 或R 5是支链或直链烷基，环烷基，芳基，芳烷基或单或稠环芳族杂环基; 制备这些化合物的方法，包含这些化合物的药物组合物和这些化合物的用途以及这些化合物和组合物在医药中的用途。

    Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
    4.
    发明授权
    Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists 失效
    喹啉-4-甲酰胺衍生物作为NK-3和NK-2受体拮抗剂

    公开(公告)号：US06780875B2

    公开(公告)日：2004-08-24

    申请号：US10358938

    申请日：2003-02-05

    申请人： Carlo Farina ,  Giuseppe Giardina ,  Mario Grugni ,  Marcel Morvan ,  Guy Marguerite Marie Gérard Nadler ,  Luca Francesco Raveglia

    发明人： Carlo Farina ,  Giuseppe Giardina ,  Mario Grugni ,  Marcel Morvan ,  Guy Marguerite Marie Gérard Nadler ,  Luca Francesco Raveglia

    IPC分类号： A61K314709

    CPC分类号： C07D401/06 ,  C07D215/52 ,  C07D401/12 ,  C07D401/14 ,  C07D413/10 ,  C07D417/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/10

    摘要： A compound, or a solvate or a salt thereof, of formula (I): wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted C5-7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is hydrogen, linear or branched C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl; R1 represents hydrogen or up to three optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-C1-6 alkylamino, R2 represents a moiety —(CH2)n—NYY2 wherein n is an integer in the range of from 1 to 9, Y1 and Y2 are independently selected from C1-6-alkyl; C1-6 alkyl substituted with hydroxy, alkoxy, C1-6 alkylamino or bis (C1-6 alkyl) amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C1-6-alkenyl; aryl or aryl-C1-6-alkyl or Y1 and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group; R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or C1-6 alkyl, R5 represents hydrogen or halogen; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

    摘要翻译： 式（I）的化合物或其溶剂化物或其盐：其中，Ar为任选取代的芳基或C 5-7环二烯基，或任选取代的C 5-7环烷​​基，或任选取代的单或稠合 环芳族杂环基团; R是氢，直链或支链C 1-6烷基，C 3-7环烷基，C 3-7环烷基烷基; R 1代表氢或最多三个选自下列的任选取代基：C 1-6烷基， 6-烯基，芳基，C 1-6烷氧基，羟基，卤素，硝基，氰基，羧基，甲酰氨基，磺酰氨基，C 1-6烷氧基羰基，三氟甲基，酰氧基，氨基或单-C 1-6烷基氨基， （CH 2）n -NYY 2，其中n是1至9的整数，Y 1和Y 2独立地选自C 1-6 - 烷基; 被羟基，烷氧基，C 1-6烷基氨基或双（C 1-6烷基）氨基取代的C 1-6烷基; C3-6环烷基; C4-6氮杂环烷基; C 1-6 - 烯基; 芳基或芳基-C 1-6 - 烷基或Y1和Y2与它们所连接的氮原子一起表示任选取代的N-连接的单或稠环杂环基; R 3是支链或直链C 1-6烷基，C 3-7 环烷基，C 4-7环烷基烷基，任选取代的芳基或任选取代的单环或稠环芳族杂环基; R 4表示氢或C 1-6烷基，R 5表示氢或卤素; 制备这种化合物的方法，包含这些化合物的药物组合物以及这些化合物和组合物在医药中的用途。

    Quinoline derivatives as NK-2 and NK-3 receptor ligands
    5.
    发明授权
    Quinoline derivatives as NK-2 and NK-3 receptor ligands 失效
    喹啉衍生物作为NK-2和NK-3受体配体

    公开(公告)号：US06613770B1

    公开(公告)日：2003-09-02

    申请号：US09856385

    申请日：2001-09-28

    申请人： Carlo Farina ,  Giuseppe Giardina ,  Mario Grugni ,  Guy Marguerite Marie Gerard Nadler ,  Luca Francesco Raveglia

    发明人： Carlo Farina ,  Giuseppe Giardina ,  Mario Grugni ,  Guy Marguerite Marie Gerard Nadler ,  Luca Francesco Raveglia

    IPC分类号： A61K314725

    CPC分类号： C07D401/06 ,  C07D215/52 ,  C07D401/14

    摘要： A compound, or a solvate or a salt thereof, of formula (I): wherein R is linear or branched alkyl; R1 represents hydrogen or up to four optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono- and di-C1-6 alkylamino; R2 represents a moiety —(CH2)n—NY1Y2 wherein n is an integer in the range of from 1 to 9, Y1 and Y2 are independently selected from hydrogen; C1-6-alkyl; C1-6 alkyl substituted with hydroxy, C1-6 alkylamino or bis (C1-6 alkyl) amino; C1-6-alkenyl; aryl or aryl-C1-6-alkyl or Y1 and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group; R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or alkyl or R4 and R together with the carbon atom to which they are attached form an optionally substituted C3-12 cycloalkyl group; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

    摘要翻译： 式（I）的化合物或其溶剂化物或其盐：其中R是直链或支链烷基; R1代表氢或最多四个选自下列的任选取代基：C 1-6烷基，C 1-6烯基 芳基，C 1-6烷氧基，羟基，卤素，硝基，氰基，羧基，甲酰胺基，磺酰氨基，C 1-6烷氧基羰基，三氟甲基，酰氧基，苯二甲酰亚氨基，氨基或单-C2和二-C6烷基氨基; R2代表 - （CH2）n-NY1Y2其中n是1至9的整数，Y1和Y2独立地选自氢; C 1-6 - 烷基; 被羟基，C 1-6烷基氨基或双（C 1-6烷基）氨基取代的C 1-6烷基; C 1-6 - 烯基; 芳基或芳基-C 1-6 - 烷基或Y1和Y2与它们所连接的氮原子一起表示任选取代的N-连接的单或稠环杂环基; R 3是支链或直链C 1-6烷基，C 3-7 环烷基，C 4-7环烷基烷基，任选取代的芳基或任选取代的单环或稠环芳族杂环基; R 4表示氢或烷基或R 4，R与它们所连接的碳原子一起形成任选取代的C 3-12环烷基; 制备这种化合物的方法，包含这些化合物的药物组合物以及这些化合物和组合物在医药中的用途。

    Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists
    8.
    发明申请
    Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists 审中-公开

    公开(公告)号：US20060235026A1

    公开(公告)日：2006-10-19

    申请号：US11425434

    申请日：2006-06-21

    申请人： Carlo Farina ,  Giuseppe Giardina ,  Mario Grugni ,  Guy Gerard Nadler

    发明人： Carlo Farina ,  Giuseppe Giardina ,  Mario Grugni ,  Guy Gerard Nadler

    IPC分类号： A61K31/496 ,  C07D403/02

    CPC分类号： C07D215/52

    摘要： Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: wherein: R1 is H or C1-6 alkyl; R2 is aryl or C3-7 cycloalkyl or heteroaryl; R3 is H or C1-3 alkyl, optionally substituted by one or more fluorines; R4 is R8R9; R8 is a single bond, C1-6 alkyl, or aryl; R9 is H, COO R10, or NR11R12; R10 is H or C1-6 alkyl; R11 and R12 are independently selected from H and C1-6 alkyl; R5 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, aryl, or a single or fused ring aromatic heterocyclic group; R6 represents H or up to three substituents independently selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- or di-C1-6 alkylamino; R7 is H or halo; a is 1-6; and any of R2, R5, R8, R10, R11 and R12 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.